PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Pasteurization”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 829 records · Page 46Linked to original sources

The effect of iron supplements and blood transfusion on iron absorption by low birthweight infants fed pasteurized human breast milk.

Using serial metabolic balances, iron absorption was measured in six preterm infants (mean gestational age 29 weeks), and two fullterm small for gestational age (SGA) infants, between day 10 and 70 after birth. They were all fed breast milk. Iron supplements (2.5--13 mg/kg day) were given from day 30. Three preterm infants received blood transfusions for anemia. During the first 30 days of life iron balance was negative in the preterm infants (mean +/- SEM = -0.10 +/- 0.02 mg/kg day) and positive in the full term SGA infants (mean +/- SEM = 0.098 +/- 0.02 mg/kg day). In infants who were not tranfused, absorption of supplementary iron was a linear function of iron intake, and corresponded closely to 34% absorption. An iron intake of 5--6 mg/kg day resulted in the absorption of amounts of iron close to those being laid down in utero. Blood transfusion was followed by a reduction in iron absorption; in two cases it became negative, becoming positive again as the hemoglobin fell below about 12.0 g/100 ml. These data show that a mechanism exists in preterm infants for the control of iron absorption which does not operate at the hemoglobin concentrations that prevail in such infants, unless they are transfused.

Absorption↗

Pasteur's stroke.

Explore the source record for details and available documents.

Cerebrovascular Disorders↗

Thermostabilization of ovotransferrin by anions for pasteurization of liquid egg white.

The effects of anions on the thermostability of ovotransferrin (oTf) were investigated. The temperature, T(m), causing aggregation of oTf was measured in the presence or absence of anions, and the denaturation temperature, T(m)(DSC), was also determined by differential scanning calorimetry (DSC) in the presence of the citrate anion. We found that some anions (phosphate, sulfate and citrate) raised temperature T(m) of oTf by about 5-7 degrees C. However, neither sodium chloride nor sodium bicarbonate raised T(m) by that much. Temperature T(m) was increased by increasing the concentration of the citrate anion, and was in good agreement with denaturation temperature T(m)(DSC), suggesting that denaturation of the oTf molecules resulted in aggregation of oTf. We also demonstrated that the anions, especially sulfate, repressed the heat-aggregation of liquid egg white. The Van't Hoff plot from the T(m) and DeltaH(d) values revealed that two anion-binding sites were concerned with heat stabilization. These binding sites may have been concerned with sulfate binding (not bicarbonate binding) that is found in the crystal structure of apo-form of oTf, since the bicarbonate anion did not raise T(m).

Animals↗

Pasteur Euroconference on future therapies for an anxious world.

The aim of this meeting was to explore the molecular targets for tomorrow's drugs with a group of European and North American speakers from the pharmaceutical industry and academia presenting both data and ideas. Several speakers considered 5-hydroxytryptamine(1B/D) (5-HT(1B/D)) receptor antagonists to be a promising target for the treatment of obsessive compulsive disorders (OCD). 5-HT moduline, a peptide modulator of the 5-HT(1B/D) receptor, presents a potentially subtle way of intervention. No clinical data are as yet available on 5-HT(1B/D) receptor antagonists. The paradox of agonists, partial agonists and antagonists at the 5-HT(1A) receptor (all having anxiolytic activity in animal models) was discussed. Although the 5-HT(1A) agonists tested in clinical trials to date have been disappointing, the clinical potential of 5-HT(1A) antagonists still has to be evaluated. Similarly, both agonists and antagonists at the 5-HT(2C) receptor have been shown to be active in animal models of anxiety. It seems, however, that 5-HT(2C) agonists may have a therapeutic potential in panic disorders and OCD, while the antagonists may be more appropriate in generalised anxiety. Cholecystokinin (CCK) has been shown to be implicated in panic attacks which can be induced by agonists at the CCK-B subtype. CCK-B antagonists are thus potential antipanic agents although this has not yet been confirmed by clinical trials. Finally, inhibition of glutamatergic neurotransmission produces anxiolytic effects in a wide-range of animal models and the new antagonists at the metabotropic glutamate receptors may have potential as anti-anxiety agents. This report focuses on the presentations that addressed novel drug candidates or potential new drug targets.

Journal Article↗